ArticleAdvances in radiation oncology2025
FLASH Stereotactic Body Radiation Therapy for Spine Tumors Using a Single-Energy Proton Pristine Bragg Peak Delivery Technique.
Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Expert consensus on clinical trial design guidelines for FLASH radiotherapy.Precision radiation oncology · 2026Article
- Proton Bragg peak flash stereotactic radiosurgery for recurrent glioblastoma reirradiation.Physics and imaging in radiation oncology · 2026Article
- Implementation of a novel pencil beam scanning Bragg peak FLASH technique to a commercial treatment planning system.Medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Purpose: To investigate the dosimetric performance and dose rate of Bragg peak FLASH (BP-FLASH) for spinal cord stereotactic body radiation therapy (SBRT). Methods and Materials: Ten consecutive patients with spinal tumors treated with conventional intensity modulated proton therapy (CONV-IMPT) SBRT (40 Gy in 5 fractions) were selected for this study. These patients were reoptimized using an in-house FLASH algorithm and a single-energy Bragg peak approach. The dose distributions and dose metrics for target coverage and critical organs-at-risk (OARs) were compared. BP-FLASH plans dose rates were calculated using an average-dose-rate. The FLASH ratios (V Results: Dosimetric analysis revealed that the BP-FLASH plans deliver a similar dose as CONV-IMPT plans to critical OARs. However, in BP-FLASH, the clinical target volume received a higher maximum dose than CONV-IMPT (115.1% versus 108.9%, Conclusions: BP-FLASH SBRT is a promising treatment for challenging spinal cord cancers, which achieved ultra-high-dose rates for FLASH effect and maintained the same dosimetry quality as the CONV-IMPT plans.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.